D
Daniel Campos
Researcher at Merck & Co.
Publications - 2
Citations - 5378
Daniel Campos is an academic researcher from Merck & Co.. The author has contributed to research in topics: NK1 receptor antagonist & Hazard ratio. The author has an hindex of 2, co-authored 2 publications receiving 5218 citations.
Papers
More filters
Journal ArticleDOI
Erlotinib in previously treated non-small-cell lung cancer.
Frances A. Shepherd,José Rodrigues Pereira,Tudor Ciuleanu,Eng Huat Tan,Vera Hirsh,Sumitra Thongprasert,Daniel Campos,Savitree Maoleekoonpiroj,Michael Smylie,Renato G. Martins,Maximiliano Van Kooten,Mircea Dediu,B. Findlay,Dongsheng Tu,Dianne Johnston,Andrea Bezjak,Gary M. Clark,Pedro Santabárbara,Lesley Seymour +18 more
TL;DR: Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects.
Journal ArticleDOI
Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone
Daniel Campos,José Rodrigues Pereira,Rick R. Reinhardt,Carlos Carracedo,Sergio Poli,Conrado Vogel,Jorge Martinez-Cedillo,Aura Erazo,Johanna Wittreich,Lars-Olof Eriksson,Alexandra D. Carides,Barry J. Gertz +11 more
TL;DR: Once daily oral administration of MK-869 was effective in reducing delayed emesis and nausea after high-dose cisplatin, however, the combination of the 5HT3 antagonist plus dexamethasone was numerically superior to MK- 869 plus DexamethAsone in reducing acute emesis.